Compare Charles River Laboratories Intl. Inc (CRL) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs HP Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while HP Inc trades at $29.21 (market cap $26.59B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays a 4.13% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | HPQ | |
|---|---|---|
Market Cap | $13.46B | $26.59B |
Sector | Health | Technology |
52-Week High | $282.00 | $30.05 |
52-Week Low | $145.57 | $18.20 |
Enterprise Value | $16.30B | $33.75B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
HPQ trades at $28.96, down 2.82% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue for 2025 reached $55.3 billion, with a net income margin of 4.45%, while valuation metrics like a P/E of 10.77 and P/S of 0.48 suggest potential undervaluation. Recent news highlights AI-driven cost savings and a profitable upgrade cycle, with Q2 FY2026 revenue up 9% year-over-year.
The outlook is mixed; HPQ benefits from solid cash flow and dividend yields near 4%, but faces risks from PC market declines and competitive pressures. Analyst consensus is cautious with a hold-heavy rating, and the stock trades above the consensus price target of $22, indicating limited upside. Investors should weigh steady profitability against industry headwinds and valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
